|
Market Closed -
Other stock markets
|
After hours 01:10:30 pm | |||
| 24.12 EUR | +2.99% |
|
24.16 | +0.17% |
| Jan. 29 | Modest Recovery for Medincell Following Sharp Decline |  |
| Jan. 28 | Medincell S.A. Reports Sales Results for the Fourth Quarter and Full 2025 | CI |
| Capitalization | 775M 920M 710M 674M 1.25B 83.48B 1.29B 8.18B 3.27B 40.14B 3.45B 3.38B 141B | P/E ratio 2026 * |
-54.8x | P/E ratio 2027 * | 214x |
|---|---|---|---|---|---|
| Enterprise value | 791M 938M 724M 688M 1.27B 85.13B 1.32B 8.34B 3.33B 40.93B 3.52B 3.45B 144B | EV / Sales 2026 * |
25x | EV / Sales 2027 * | 18.3x |
| Free-Float |
61.66% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MedinCell S.A.
| 1 day | +2.99% | ||
| 1 week | +5.05% | ||
| Current month | +6.91% | ||
| 1 month | -8.71% | ||
| 3 months | -19.49% | ||
| 6 months | +53.34% | ||
| Current year | -4.29% |
| 1 week | 22.88 |  | 24.58 |
| 1 month | 22.32 | | 29.3 |
| Current year | 22.32 | | 29.3 |
| 1 year | 12 | | 39.68 |
| 3 years | 5.25 | | 39.68 |
| 5 years | 4.73 | | 39.68 |
| 10 years | 4.35 | | 39.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 62 | 2003-01-08 |
Stéphane Postic
DFI | Director of Finance/CFO | 52 | 2023-08-31 |
Richard Malamut
CTO | Chief Tech/Sci/R&D Officer | 67 | 2022-05-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Christophe Douat
BRD | Director/Board Member | 62 | 2003-01-08 |
Philippe Guy
CHM | Chairman | - | 2024-03-12 |
Virginie Lleu
BRD | Director/Board Member | - | 2016-05-24 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.99% | +5.05% | +58.89% | +202.63% | 923M | |
| -0.43% | -7.79% | +18.02% | +191.34% | 918B | |
| +0.92% | +2.63% | +54.12% | +47.85% | 574B | |
| -0.89% | +1.68% | +15.08% | +43.60% | 393B | |
| +1.62% | -1.05% | +23.80% | +27.79% | 366B | |
| +1.74% | +3.71% | +25.56% | +53.07% | 301B | |
| +4.62% | +7.41% | +27.48% | +29.73% | 300B | |
| +1.20% | +0.25% | +37.07% | +8.28% | 291B | |
| -2.62% | +0.67% | -48.90% | -38.29% | 223B | |
| -0.22% | -0.00% | +23.44% | +50.29% | 196B | |
| Average | +0.81% | +0.83% | +23.46% | +61.63% | 356.36B | |
| Weighted average by Cap. | +0.49% | +1.25% | +23.22% | +72.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 31.58M 37.47M 28.9M 27.46M 50.92M 3.4B 52.64M 333M 133M 1.63B 141M 138M 5.74B | 42.78M 50.75M 39.15M 37.2M 68.97M 4.61B 71.31M 451M 180M 2.21B 190M 186M 7.78B |
| Net income | -13.04M -15.47M -11.93M -11.34M -21.02M -1.4B -21.73M -138M -54.94M -675M -58.02M -56.82M -2.37B | 7.25M 8.6M 6.64M 6.3M 11.69M 781M 12.09M 76.52M 30.55M 375M 32.26M 31.6M 1.32B |
| Net Debt | 15.35M 18.21M 14.05M 13.35M 24.75M 1.65B 25.59M 162M 64.69M 795M 68.31M 66.9M 2.79B | 6.95M 8.25M 6.36M 6.04M 11.21M 748M 11.59M 73.35M 29.29M 360M 30.93M 30.29M 1.26B |
Employees
145
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-11 | 24.12 € | +2.99% | 129,699 |
| 26-02-10 | 23.42 € | -3.70% | 108,552 |
| 26-02-09 | 24.32 € | +2.36% | 77,731 |
| 26-02-06 | 23.76 € | +1.89% | 78,863 |
| 26-02-05 | 23.32 € | +1.57% | 51,429 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
23.42EUR
Average target price
35.26EUR
Spread / Average Target
+50.57%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MEDCL Stock
Select your edition
All financial news and data tailored to specific country editions
